Continued targeting of androgen receptor signalling: a rational and efficacious therapeutic strategy in metastatic castration-resistant prostate cancer.
作者信息
Bianchini Diletta, de Bono Johann S
机构信息
Section of Medicine, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.
出版信息
Eur J Cancer. 2011 Sep;47 Suppl 3:S189-94. doi: 10.1016/S0959-8049(11)70164-2.
Abstract
摘要
相似文献
1
Continued targeting of androgen receptor signalling: a rational and efficacious therapeutic strategy in metastatic castration-resistant prostate cancer.
Eur J Cancer. 2011 Sep;47 Suppl 3:S189-94. doi: 10.1016/S0959-8049(11)70164-2.
2
N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer.
Endocr Relat Cancer. 2010 May 18;17(2):469-79. doi: 10.1677/ERC-10-0015. Print 2010 Jun.
3
Overcoming castration resistance in prostate cancer.
Curr Opin Urol. 2012 May;22(3):167-74. doi: 10.1097/MOU.0b013e3283523b8b.
4
Novel agents for the management of castration-resistant prostate cancer.
Curr Opin Urol. 2012 May;22(3):175-82. doi: 10.1097/MOU.0b013e3283523ba0.
5
Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
Endocr Relat Cancer. 2011 Jul 11;18(4):505-17. doi: 10.1530/ERC-11-0017. Print 2011 Aug.
6
Targeting continued androgen receptor signaling in prostate cancer.
Clin Cancer Res. 2011 Jun 15;17(12):3876-83. doi: 10.1158/1078-0432.CCR-10-2815.
7
Cytology of metastatic prostate cancer following orchiectomy and antiandrogen therapy: a diagnostic challenge.
Diagn Cytopathol. 2008 Jul;36(7):499-502. doi: 10.1002/dc.20814.
8
Drug insight: role of the androgen receptor in the development and progression of prostate cancer.
Nat Clin Pract Oncol. 2007 Apr;4(4):236-44. doi: 10.1038/ncponc0765.
9
Androgen receptor: role and novel therapeutic prospects in prostate cancer.
Expert Rev Anticancer Ther. 2008 Sep;8(9):1495-508. doi: 10.1586/14737140.8.9.1495.
10
Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation.
Nat Clin Pract Urol. 2007 Feb;4(2):82-94. doi: 10.1038/ncpuro0700.
引用本文的文献
1
Differential but Concerted Expression of HSD17B2, HSD17B3, SHBG and SRD5A1 Testosterone Tetrad Modulate Therapy Response and Susceptibility to Disease Relapse in Patients with Prostate Cancer.
Cancers (Basel). 2021 Jul 12;13(14):3478. doi: 10.3390/cancers13143478.
2
Radium-223 chloride: a new treatment option for metastatic castration-resistant prostate carcinoma.
Drugs R D. 2012 Dec 1;12(4):227-33. doi: 10.2165/11636250-000000000-00000.
Zotero 插件